Objective
Oncolinx has developed a novel molecular platform allowing for non-invasive and highly effective cancer cures. The platform carries a killing drug (Azonafide), linked to an antibody, specifically targeting and destroying only malignant tumour cells. These molecular complexes are called Antibody Drug Conjugates (ADCs) and represent a strong, valid alternative to current chemotherapies. Oncolinx’s innovative linker/payload technology enables the Azonafide platform to perform a sensitive discrimination between healthy and cancer cells, thereby avoiding adverse side-effects of chemotherapy. ADCs enhance the effectiveness of a systemic treatment and have the advantage of targeting only tumour sites within the same therapy. Oncolinx’s drugs are effective against drug resistant cancers, as well as cancer stem cells (CSCs)—cells directly responsible for drug-resistance, metastasis, and relapse. In addition, Oncolinx’s technology activates the immune system against the tumour, which is an integral hallmark of durable responses. Although Oncolinx’s platform is designed to be adopted for drug-resistant breast cancers as first application, the Azonafide payload potency has been validated across all NCI-60 cell lines screening for different tumour types. The NCI-60 Human Tumour Cell Lines Screen also showed that the Azonafide payload, when conjugated with Oncolinx linker technology to specific antibodies, can kill up to 98.2% of cancer cells while remaining non-toxic to cells that do not express the antigen. NCI-60 screening has shown subnanomolar-picomolar potency across cancers (1x10-9M). While a variety of ADCs compound are currently developed and tested, only two ADCs have been approved so far. However, because Azonafide platform has a unique mechanism of action, Oncolinx can exclusively target slow growing cancers, drug resistant cancers, and other cancers that cannot be treated by the technologies of the two competitors (Seattle Genetics and ImmunoGen).
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
- medical and health sciences clinical medicine oncology breast cancer
- medical and health sciences basic medicine pharmacology and pharmacy pharmacokinetics
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
SE1 0BL LONDON
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.